Current PSA level-20 or above - Page 5 of 5 Posts on Medivizor
Navigation Menu

Current PSA level-20 or above Posts on Medivizor

Phase 3 clinical trial comparing intermittent hormonal therapy and continuous hormonal therapy in patients with advanced prostate cancer

Phase 3 clinical trial comparing intermittent hormonal therapy and continuous hormonal therapy in patients with advanced prostate cancer

Posted by on May 7, 2013 in Prostate cancer | 0 comments

In a nutshell The present study compared the effectiveness of two kinds of hormonal therapy in advanced prostate cancer (cancer that has spread beyond the prostate gland). These are intermittent hormonal therapy (IHT) and continuous androgen-deprivation therapy (ADT). In this study, IHT was similar to ADT in terms of survival, but showed better quality...

Read More

Denosumab: decrease in spread of bone cancer in men with prostate cancer (not responsive to hormone therapy & surgery)

Denosumab: decrease in spread of bone cancer in men with prostate cancer (not responsive to hormone therapy & surgery)

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell The present study assessed the efficiency of a drug named Denosumab in delaying the spread of prostate cancer to the bone in men with resistant prostate cancer (not responding to hormone therapy and surgery). The results show that the drug tested delayed bone involvement by few months.  Some background Bone metastases are...

Read More

Non-cancerous cells in the prostate contribute to the aquired tumor resistance to chemotherapy

Non-cancerous cells in the prostate contribute to the aquired tumor resistance to chemotherapy

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

Regretfully, metastatic forms of prostate cancer (spread to distant sites via the blood system) treated with chemotherapy often acquire resistance to the drug, partially due to the repetitive nature of treatment. Resistance leads to tumor progression and treatment failure. This scientific article proposes a novel therapeutic target named WNT16B that...

Read More

Evaluating survival rates in patients with prostate cancer treated with low-dose-rate brachytherapy

Evaluating survival rates in patients with prostate cancer treated with low-dose-rate brachytherapy

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell The present study evaluated survival rates in patients with prostate cancer (PC) treated with Low-dose-rate prostate brachytherapy (LDR-PB). The main findings were that LDR-PB alone or combined with hormone therapy offers excellent survival in PC patients. Some background Prostate cancer is the most common type of cancer in men....

Read More

Experimental drug – Enzalutamide – moderately increases survival in patients with advanced prostate cancer

Experimental drug – Enzalutamide – moderately increases survival in patients with advanced prostate cancer

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell This clinical trial evaluated the survival benefits of a drug named Enzalutamide (Xtandi) for patients with non-responsive (refractory) advanced prostate cancer previously treated with chemotherapy. Main findings: Enzalutamide prolonged survival by approximately 5 months and reduced the risk of death by 37%. Some background The...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor